Background: Pregnant women with anemia, especially those with severe anemia, run the risk of having poor physical activity levels, higher maternal morbidity, and increased death. Also, their newborns experience adverse effects such as perinatal mortality, intrauterine growth restriction, premature delivery, low birth weight, and fetal anemia. Objective: The aim of the current study was to compare the bioavailability, safety, efficacy and hematological responses to oral ferrous bisglycinate supplementation and sucrosomal iron in the treatment of iron deficiency anemia (IDA) in pregnant women. Patients and methods: A clinical trial was conducted at Antenatal Care Outpatient Clinic of Zagazig University Hospitals. The clinical trial included 66 oregnant women in their second and third trimester with IDA (hemoglobin level ≤10 g/dl). Participants were divided two groups; Group 1included cases who received ferrous bisglycinate supplementation and Group 2 included cases who received sucrosomal iron therapy. All Pregnant women were subjected to a full medical history, physical examination, and laboratory testing, including CBC, iron, ferritin, and total iron binding capacity (TIBC). Results: In groups I and II, there was significant increase of RBCs, hemoglobin, HCT%, MCV, MCHC and ferritin, iron and TIBC at final values compared to the corresponding basal value. The improvement of CBC findings, ferritin, iron and TIBC was more significant in group 2 cases who received sucrosomal iron therapy. Conclusion: Oral sucrosomal iron therapy is more effective and acceptable than oral iron salts for the treatment of IDA.